EFFECTS OF REFORMER PILATES ON FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN WOMEN
THE EFFECTS OF REFORMER PILATES EXERCISES APPLIED IN WOMEN ON FUNCTIONAL CAPACITY, HEART RATE, BODY COMPOSITION AND QUALITY OF LIFE
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Istanbul
-
Istanbul, Istanbul, Turkey (Türkiye), 34000
- Istanbul Aydin University- FLC Concept Healthy Living Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female participants aged between 20 and 40 years
- Healthy individuals capable of performing exercise
- Voluntary participation in the study
- Ability to attend Pilates sessions regularly
Exclusion Criteria:
- Male participants
- Receiving any form of physical therapy intervention
- History of surgery
- Severe spinal pathologies
- Neurological disorders
- Cardiopulmonary diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Reformer Pilates Group
Participants received supervised reformer pilates exercises twice a week for 8 weeks.
|
Participants performed supervised reformer pilates exercises twice a week for 8 weeks.
|
|
Other: Control Group
Participants followed a home-based exercise program twice a week for 8 weeks without supervised reformer pilates.
|
Participants performed a home-based exercise program on their own for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Capacity (6-Minute Walk Test)
Time Frame: At baseline and after 8 weeks
|
Functional capacity will be assessed using the 6-minute walk test (6MWT).
The distance walked in meters (m) will be recorded.
|
At baseline and after 8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life (Short Form-12, SF-12)
Time Frame: At baseline and after 8 weeks
|
Quality of life will be assessed using the Short Form-12 (SF-12) questionnaire.
Physical Component Summary (PCS) and Mental Component Summary (MCS) scores will be calculated.
Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
|
At baseline and after 8 weeks
|
|
Body Fat Percentage (%)
Time Frame: At baseline and after 8 weeks
|
Body fat percentage (%) will be assessed using bioelectrical impedance analysis (BIA, InBody device).
|
At baseline and after 8 weeks
|
|
Heart Rate (beats per minute, bpm)
Time Frame: At baseline and after 8 weeks
|
Heart rate was measured using a pulse oximeter at the 20th minute of the exercise session only in the intervention group, both at the first session and at the end of 8 weeks.
|
At baseline and after 8 weeks
|
|
Skeletal Muscle Mass (kg)
Time Frame: At baseline and after 8 weeks
|
Skeletal muscle mass (kg) will be assessed using bioelectrical impedance analysis (BIA) with an InBody device under standardized conditions.
|
At baseline and after 8 weeks
|
|
Body Weight (kg)
Time Frame: At baseline and after 8 weeks
|
Body weight (kg) will be assessed using bioelectrical impedance analysis (BIA) with an InBody device under standardized conditions.
|
At baseline and after 8 weeks
|
|
Body Mass Index (kg/m²)
Time Frame: At baseline and after 8 weeks
|
Body mass index (kg/m²) will be calculated as body weight (kg) divided by height squared (m²).
Body weight will be obtained using bioelectrical impedance analysis (BIA) with an InBody device.
|
At baseline and after 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ayca S Sensoy, PT, MSc Student, Istanbul Aydın University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 268/2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.